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ABSTRACT  A panel of monoclonal antibodies (Mab's) has been raised against human platelet 
thrombospondin  (TSP). One Mab, designated A2.5, inhibits the hemagglutinating activity  of 
TSP and immunoprecipitates  the NH2 terminal 25 kD heparin binding domain of TSP (Dixit, 
V. M., D. M. Haverstick, K. M. O'Rourke,  S. W. Hennessy, G. A. Grant, S. A. Santoro, and W. 
A. Frazier, 1985, Biochemistry,  in press). Another Mab, C6.7, blocks the thrombin-stimulated 
aggregation of  live  platelets and  immunoprecipitates  an  18-kD fragment  distinct  from  the 
heparin binding domain (Dixit, V. M., D. M. Haverstick, K. M. O'Rourke,  S. W. Hennessy, G. 
A. Grant, S. A. Santoro, and W.  A.  Frazier, 1985, Proc.  Natl.  Acad.  Sci. 82:3472-3476).  To 
determine  the  relative  locations  of the  epitopes  for these Mabs in  the  three-dimensional 
structure of TSP, we have examined TSP-Mab complexes by electron  microscopy of rotary- 
shadowed proteins. The TSP molecule is composed of three 180-kD subunits, each of which 
consists of a small globular domain (~8 nm diam) and a larger globular domain (~16 nm diam) 
connected  by a thin, flexible  strand. The subunit  interaction  site is on the thin connecting 
strands, nearer the  small globular  domains. Mab  A2.5  binds to  the  cluster of three  small 
domains, indicating that this region contains the heparin binding domain and thus represents 
the NH2 termini  of the TSP peptide chains. Mab C6.7 binds to the large globular domains on 
the side opposite the point at which the connecting strand enters the domain, essentially the 
maximum  possible distance from  the  A2.5  epitope.  Using high sensitivity automated  NH2 
terminal  sequencing of TSP chymotryptic peptides we have ordered these fragments within 
the TSP peptide  chain  and  have confirmed  that the epitope for C6.7 in  fact lies near the 
extreme COOH terminus of the ~)eptide chain. In combination with other data, we have been 
able to construct a map of the linear order of the identified  domains of TSP that indicates that 
to a large extent, the domains are arranged co-linearly with the peptide chain. 
Thrombospondin  (TSP) t  is  essential  in  the  aggregation  of 
human platelets (1).  We have identified a  monoclonal anti- 
body against TSP that can block the aggregation of gel-filtered 
human  platelets  stimulated  with  thrombin  or  A23187  (1). 
Other investigators have found that  polyclonal antisera di- 
rected against either intact TSP (2, 3) or the heparin binding 
domain of bovine TSP (4)  can  inhibit  platelet aggregation. 
Abbreviations used in this paper.  Mab, monoclonal antibody; TSP, 
thrombospondin. 
These recent data have provided the first direct demonstration 
that TSP is necessary for platelet aggregation. TSP is secreted 
from platelets upon their activation by thrombin, collagen, or 
other activating agents (5-8) and binds to receptors on the 
platelet surface when divalent cations are present (9). TSP has 
been identified as an endogenous lectin of platelets (10),  and 
we have characterized the agglutinating activity of the purified 
protein towards trypsinized,  fixed human erythrocytes (11) 
and fixed activated platelets (12).  The differential effects of 
heparin and fibrinogen as inhibitors of these two activities of 
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activated platelets are in some way qualitatively distinct (1 l, 
12). 
TSP is  a  trimeric giycoprotein whose  identical  (13)  Mr 
180,000  subunits  are  linked  by disulfide bonds  (6).  Until 
recently, there was some confusion about the appearance of 
the protein when subjected to rotary shadowing and electron 
microscopy. Images of rotary-shadowed TSP obtained with 
electron microscopy have shown molecules with both three 
and  four globular  domains  connected by  thinner  strands 
within the same sample (14,  15), a result difficult to reconcile 
with a trimeric structure of identical chains. Recently, Lawler 
et al. (16) have obtained images of the protein in which one 
of the four large globular domains is often resolved into three 
smaller globular regions. Thus, when these collapse together, 
the molecule appears as four globular domains. The report of 
three globular domains is explained by the facile removal of 
these small domains by proteolysis (l 6). A variety of  proteases 
will digest native TSP, yielding protease-resistant regions that 
appear to represent compact areas of protein structure that 
contain binding sites  for ligands with which TSP interacts. 
Thus far, fragments have been identified that represent do- 
mains that bind heparin (13,  16-18), fibrinogen (19), type V 
collagen (20), fixed erythrocytes (11), and platelets ( l, 12). 
To begin dissecting the structure of this large protein and 
to relate the functional domains to the structure of the mol- 
ecule, we have generated a  panel of monoclonal antibodies 
(Mab's)  against  both  native,  calcium-replete TSP and  the 
denatured protein. This panel has been characterized in terms 
of the effect of each Mab on three functional assays for TSP: 
hemagglutination (21), agglutination of fixed, activated plate- 
lets (21), and aggregation of  live platelets (1). Mab C6.7 blocks 
the  thrombin-  and  A23187-stimulated  aggregation  of live, 
washed  platelets  (1)  and  the  hemagglutinating  activity  of 
purified TSP (21). In contrast, A2.5 blocks the hemagglutin- 
ation activity of TSP and the agglutination of fixed, activated 
platelets (2 l). We have identified protease-resistant domains 
that  contain  the  epitopes for these  two  antibodies.  When 
native TSP is digested with chymotrypsin or thermolysin, a 
25-kD fragment is rapidly liberated which binds to heparin- 
Sepharose (13) and is immunoprecipitated with Mab A2.5 
(21).  Heparin  inhibits  the  binding of A2.5  to intact  TSP, 
further confirming that this Mab recognizes the heparin bind- 
ing domain of TSP. Automated protein sequencing of the 
isolated heparin binding domain and the intact TSP peptide 
chain has revealed that both have the same NH2 terminal 
sequence, and hence the heparin binding domain is located 
at the very NH2 terminus of TSP (13,  15,  18). The other 
fragment present in the digests  at early times has an Mr of 
140,000 and binds to fibrinogen-Sepharose (19), fixed eryth- 
rocytes (11), and fixed activated platelets (12) even though it 
no longer contains the heparin-binding domain. This 140-kD 
piece subsequently decays to yield peptides of 120 and 18 kD 
(1), which are disulfide linked in the absence of reductants. 
After separating the  120- and  18-kD chains, we have shown 
that Mab C6.7 binds only the small 18-kD peptide, and not 
the  120-kD fragment (1).  Thus it would appear that Mabs 
A2.5 and C6.7 bind to quite distinct regions of TSP. 
In this study, we have used these Mabs in conjunction with 
electron microscopy and high sensitivity amino acid sequenc- 
ing techniques to map the positions of the epitopes for these 
two antibodies on the TSP trimer. The results of  the sequenc- 
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ing experiments also allow the assignment of the linear order 
of the domains of TSP within the peptide chain. 
MATERIALS  AND  METHODS 
Materials:  Calcium-replete  TSP was purified from the supernatant of 
thrombin activated platelets as described (13). The production,  specificity, and 
biochemical characterization  of the Mab's against  TSP, A2.5, and C6.7, has 
been described (I, 21). For use in ultrastructural  analyses, these antibodies were 
purified  from ascites  fluid by ammonium sulfate precipitation  followed by 
affinity chromatography  on goat anti-mouse gamma-globulin bound to Seph- 
arose (Cappei Laboratories,  Malvern,  PA). In some cases it was necessary to 
remove  traces  of contaminating  fibronectin  on a  gelatin-Sepharose column. 
The purity of the Mab's,  both of which  are  IgGs, was determined  by SDS 
PAGE. Reagents for sequence analysis were obtained from Applied Biosystems, 
Inc. (Foster City, CA). Reagents for SDS gels were from Bio-Rad Laboratories 
(Richmond,  CA). 
Electron Microscopy:  TSP (200 ~l) in Tris-buffered saline (20 mM 
Tris-HC1, 150 mM NaCI, pH 7.6) at a concentration  of 200 #g/ml was mixed 
with an equal volume of  glycerol and placed into an all-glass nebulizer equipped 
with a rubber bulb (Ted Pella, Inc., Tustin, CA) for spraying onto 3-ram-square 
chips of freshly cleaved mica.  The mica chips were attached  by Scotchbrand 
double-stick tape to a clean piece of cardboard  which was held in a vertical 
position.  The mouth of the nebulizer  was held 2-3  in  from the cardboard 
horizontal to the row of mica chips, and the rubber bulb was squeezed several 
times until  a  cloud  of vapor could  be seen emerging from the mouth and 
reaching to the cardboard.  To examine  TSP-Mab  complexes, 200 ~l TSP at 
200 #g/ml in Tris-buffered saline and 200 #l Mab at 50 #g/ml in Tris-buffered 
saline were incubated  at 4°C for 2 h. Glycerol  was added  to the TSP-Mab 
samples to a final concentration  of 50% before they were sprayed onto freshly 
cleaved mica as described above. Immediately after samples were sprayed, the 
mica  chips, still attached  to a  square  of cardboard,  were transferred  to the 
vacuum chamber of a vacuum evaporator  (model  DV-502, Denton Vacuum 
Inc., Cherry Hill, N  J) in which they were rotary shadowed with tungsten (0.02- 
in-diam wire at 33 mA current) at a starting angle of 8  ° and then carbon coated 
to produce a replica. Tungsten-carbon replicas were removed  from the mica 
chips by being floated off onto the surface of a drop of distilled water. The 
replicas were then picked up on 300 mesh copper grids and viewed through a 
Phillips 201  transmission  electron  microscope.  Photographic  negatives were 
reversed before printing. 
Amino Acid Sequencing:  Chymotryptic digests of TSP in the pres- 
ence and absence of Ca  ++ (5 mM EDTA) were performed as described (1,  13, 
21) and analyzed on SDS gels. Preparative  digests were run under identical 
conditions  and separated on SDS slab gels in a wide sample slot flanked by 
prestained molecular weight standards. Gels were stained with Coomassie Blue 
and the bands were excised and electroeluted  as described (13). The soluble 
peptides  were loaded  onto the sample disk  of the vapor phase  amino acid 
sequencer (model 470A, Applied Biosystems, Inc.). Alternatively, the unstained 
SDS gels were electrophoretically  transferred  onto activated  glass fiber filter 
paper which was then stained  with Coomassie Blue, and the bands were cut 
out. These glass fiber strips containing  the electroblotted peptides were placed 
directly on the sample disk of the sequencer (2 la).-Phenylthiohydantoins  were 
identified by high-performance  liquid  chromatography  after automated con- 
version. All peptides were sequenced at least twice and most were sequenced 
after both electroelution and electroblotting. Initial yields were comparable to 
those obtained  for the electroelution of standard  proteins, and repetitive yields 
with the two methods were comparable and averaged from 93 to 95%. Amounts 
of the peptides sequenced in each run were between 100 and 200 pmol. 
R  ES U LTS 
U[trastructure of TSP 
Visualization of the TSP molecule in the electron micro- 
scope revealed it  to be  a  trimeric structure  (Fig.  1),  each 
subunit consisting of a large globular region 16.96 _  2.02 nm 
in  diameter  attached  to  a  narrow  arm  bearing  a  smaller 
globular region, 8.09 -+ 2.02 nm in diameter, at the opposite 
end (Fig.  2).  These measurements are uncorrected for the 
thickness of the carbon coating. We believe that this structure 
corresponds to the 180-kD subunit observed upon SDS PAGE 
of TSP (13). To form the native trimeric molecule, the sub- 
units appear to be attached to one another at a single junc- 
Monoclonal Antibodies against Human Platelet Thrombospondin  1435 FIGURE 2  (A)  Diagrammatic  representation of the  TSP  subunit. 
The smaller of the globular domains represents the NH2 terminus 
of the peptide chain.  Three subunits  are joined at the point indi- 
cated by the arrow to form the native trimeric molecule depicted 
inB. 
fional point that lies near the smaller globular region (Fig.  1, 
b-g). The  length  of the  arm  between the  point of subunit 
attachment and the large globular head was -15.95  +  4.05 
nm; however, this distance was difficult to measure precisely 
since the arms could have become folded during the drying 
and consequent collapse of the TSP molecules before rotary 
shadowing  and  replication.  The  difficulty of obtaining  an 
accurate arm length  determination  is reflected in  the  large 
variability observed in the lengths of subunit arms shown in 
Fig.  1. These images suggest  that the arms are quite flexible 
and  can  assume  various  orientations.  The  small  globular 
regions could not be resolved in all views of  the TSP molecule, 
and, therefore, the structure sometimes appeared to have four 
large globular regions, as has been reported by other labora- 
tories (14-16).  In  many views,  the  large globular domains 
appear to have clefts running through them as though they 
might be composed of subdomains.  This idea is consistent 
with  proteolysis experiments in  which  stable  fragmen~  of 
120, 70, and  18 kD are seen to arise from the 140-kD species 
(1,  13, 20, 21). 
FIGURE  1  Rotary-shadowed  replicas of calcium-replete TSP. The 
trimeric  molecule consists of three  large globular domains with 
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narrow connecting strands joined together at one point and three 
smaller globulai" domains close to the junctional region.  Ink draw- 
ings of the samples shown in b, d, and f are presented in c, e, and 
g, respectively,  to assist in interpretation of the photomicrographs. 
(a) x  133,500. (b, d, f) x  234,500. TSP-Mab Complexes 
The ultrastructure of  the antibody-antigen complex formed 
between TSP and Mab A2.5 is shown in Fig. 3. The Mab's in 
these photographs were identified by their slightly larger size 
relative to  the  large  ball  of TSP and  by  their  somewhat 
triangular shape (inset, Fig.  3, g and h). In many cases, the 
domain structure of the antibodies can be seen, particularly 
the cleft separating the two Fab regions (e.g., Figs. 3 e and 4, 
c, e, and g). Mab A2.5, which reacts with the heparin binding 
domain of TSP (21), was clearly attached to the area of the 
molecule where the small globular heads are found (Fig. 3, a- 
h).  Frequently, binding of A2.5  seemed to have forced all 
three of the connecting strands together so that the large balls 
also became pushed together (Fig. 3, a-J) rather than splayed 
out randomly as in views of TSP alone (Fig.  1). This effect 
was  seen  in  54%  of 218  Mab-TSP complexes with  A2.5, 
whereas only  19%  of 297 TSP molecules without a bound 
A2.5  antibody molecule displayed this  conformation. The 
clustering of the large globular regions could be indicative of 
the conformational change in TSP produced by interaction 
with Mab A2.5 that has been suggested  by biochemical ex- 
periments. For example, it has been noted that A2.5 inhibits 
not only the hemagglutinating activity of TSP (21) but also 
its binding to heparin (21), plasminogen, and type V collagen 
(unpublished data). The inhibition of  heparin binding by A2.5 
is presumably caused directly by steric blocking of  the heparin 
binding site, since A2.5 immunoprecipitates this domain from 
digests  of TSP (21).  However, it is unlikely that all of the 
binding sites for these other functions of TSP reside on the 
FIGURE 3  Rotary-shadowed replicas of A2.5 attached to calcium-replete  TSP. The Mab can be identified by its size and triangular 
shape (see inset, g and h). In most examples, binding of A2.5 results in a conformational change in TSP which forces the larger 
globular regions together on one side of the complex (a, c, e). x  234,500. 
FiGure 4  Rotary-shadowed  replicas of C6.7 bound to calcium-replete TSP. The Mab is attached to the outer surface of the large 
globular domain, x  234,500. 
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clear that the binding site for type V collagen is not on the 
heparin binding domain (20) and the 140-kD fragment, which 
lacks the heparin binding domain binds to erythrocytes and 
platelets (1 I, 12). 
The complex formed between TSP and Mab C6.7 is shown 
in Fig. 4. In this case, the antibody binds to the large globular 
domain  of the  TSP molecule, at  the  opposite end of the 
subunit from the A2.5 binding site. Usually, binding of C6.7 
did not affect the spreading of the long arms of TSP on the 
mica surface, but, occasionally, where the antibody appeared 
to  be  cross-linking two  large globular heads  on  the  same 
molecule, the arms were again all lying close together (Fig. 4, 
g and h). Thus, it seems possible that C6.7 could also produce 
a conformational change in TSP by cross-linking domains on 
different subunits of the same trimer. However, this appears 
to be a relatively rare event, even at the ratio of ~ 1 mol TSP 
to  1 mol Mab used in these studies.  Only 10% of the TSP- 
C6.7 complexes ( 177 scored) showed cross-linking of  the large 
globular regions. 
Sequencing of TSP Fragments 
It has been established that the heparin binding domain of 
TSP, and hence the epitope for Mab A2.5, lies at the NH2 
terminus of the TSP subunit (13,  15,  16,  18). The results 
presented above suggest that the distant epitope for Mab C6.7 
might lie near the COOH terminus of  the molecule. Digestion 
of TSP with chymotrypsin in the presence of Ca  ÷+ results in 
rapid liberation of the heparin binding domain from the NH2 
terminus with production ofa 140-kD fragment (Fig. 5). This 
large fragment is subsequently cleaved to yield a  120- and an 
18-kD piece linked to it by disulfide bonds, which contains 
the C6.7 binding site (1). In Fig.  5 it is seen that the  18-kD 
fragment becomes more intense in parallel with the  120-kD 
species while the 140-kD fragment disappears. We have pre- 
viously determined  the  amino  acid  sequence  at  the  NH2 
terminus of  this 18-kD peptide, but to order it within the 140- 
kD fragment, more data were needed. We reasoned that if the 
18-kD peptide were liberated from the COOH terminus of 
the 140-kD species, then the 120-kD peptide might have the 
same NH2 terminus as the 140-kD peptide if further digestion 
had not occurred at that end of the chain.  Since the only 
means of preparing pure samples of these peptides is SDS gel 
electrophoresis, we undertook the microsequencing of these 
very large peptides eluted from SDS slab  gels. Fig.  6A is a 
schematic diagram of the chymotryptic digestion of TSP in 
the presence of  Ca  ÷+ ion. The sequences obtained for the 1-40- 
and  the  120-kD  peptides are  indicated  in  Fig.  6  and  are 
identical for the  11  residues that could be interpreted with 
confidence. This common sequence is Ile-Gly-His-Lys-Thr- 
Lys-Asp-Leu-Gln-Ala-Ile-. The sequence of the  18-kD pep- 
tide, which has been previously determined (1), is shown in 
Fig. 6. Thus the 18-kD fragment containing the C6.7 epitope 
must be removed from the COOH terminus of the  140-kD 
chain to generate the 120 kD species. 
In the absence of Ca  ÷÷ (5 mM EDTA), the 140- and  120- 
kD  species  are not  stable  in  chymotryptic digests  (Fig.  5). 
Instead, the largest stable fragment found is  70  kD and is 
thought to represent the type V collagen binding domain of 
TSP (20).  Since the 25-kD heparin binding domain is pro- 
duced in either the presence or absence of Ca  ÷+ (13-17), a 
cleavage must occur at roughly the same site at the COOH 
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terminus of the heparin binding domain. To determine if this 
cleavage might be the same one as that which gives rise to the 
140/120-kD fragments (above), we eleetroblotted the 70-kD 
fragment and subjected it to sequence analysis.  These results, 
shown in Fig.  6B, indicate that the 70-kD fragment has an 
NH2 terminal sequence identical to that of the  140/120-kD 
peptides. The 80-kD peptide shown in Fig.  6 is a transient 
intermediate in the digest that decays to the 70 kD species 
(Fig. 5). We infer that it must also have the same NH2 terminal 
sequence as the 70-kD species, but this has not been directly 
determined. We also analyzed the 25-kD species produced in 
the presence of EDTA and found that it is in fact identical to 
the heparin binding domain obtained in the presence of Ca  ÷+ 
(13).  Thus, even in the presence of EDTA, which induces 
dramatic conformational changes in TSP (14-17), the precise 
cleavage site between the heparin binding domain and the 
rest of the peptide chain is maintained. 
In summary, these results indicate that generation of the 
140-kD fragment is a primary event in the proteolysis of TSP 
and that all subsequent cleavages that give rise to the smaller 
fragments observed in either the presence or absence of Ca  ++ 
occur at the COOH terminus of the  140-kD peptide chain. 
The main conclusion for the Mab mapping studies is that 
whereas the heparin binding domain lies  at the very NH2 
terminus of the TSP chain, the 18-kD fragment that contains 
the epitope for C6.7, and by inference, the binding site(s) for 
platelets or platelet-associated proteins, resides at the COOH 
terminus of TSP. This conclusion is also consistent with the 
electron micrographs of TSP-C6.7 complexes in which this 
Mab binds to the opposite end of the subunit from Mab A2.5 
that binds to the NH2 terminal heparin binding domain. 
DISCUSSION 
Electron  microscopy of tungsten-shadowed,  carbon-coated 
replicas of calcium-replete TSP has shown it to be a trimer 
composed of subunits that contain a small globular domain, 
a thin connecting strand, and a larger globular domain (ref- 
erence  16  and  this study). We  have used  a  Mab  directed 
against the  NH2 terminal heparin binding domain (21)  to 
identif~¢ the  small  globular  region  as  the  heparin  binding 
domain and hence mark the NH2 terminus of the peptide 
chain as it exists in the three-dimensional configuration of 
the protein. Lawler et at. (16) have independently arrived at 
precisely the same model of TSP structure. They also used a 
monoclonal antibody directed against the heparin domain to 
identify the small domain, which they refer to as globular 
region N. It appears, however, that their Mab, called MA-I1, 
has no discernible effects on TSP function and does not cause 
the clustering of the large globular domains, referred to as 
globular region C (16), which we have noted to result from 
the binding of our Mab A2.5 to TSP (Fig. 4). We suggest that 
A2.5  does this  by binding to  two of the  heparin  binding 
domains simultaneously, thus cross-linking two subunits of 
the trimer at their NH2 termini. A2.5 inhibits both the hem- 
agglutination activity of TSP and the agglutination of fixed, 
activated platelets by purified TSP (21) yet has no effect on 
the aggregation of  live platelets (1). It also inhibits the binding 
of TSP to sulfatides (22),  plasminogen, and type V collagen 
(unpublished data).  These multiple, diverse effects of Mab 
A2.5  can be explained by its dramatic conformational reo- 
rientation of the TSP molecule (Fig.  3). Thus, any function 
mediated by a  site on the large globular domain could be FIGURE  5  The  time  course  of 
digestion of TSP by 0.5% (wt/wt) 
chymotrypsin in the presence (A) 
and absence (B, 5 mM  EDTA) of 
calcium. The SDS  gels were run 
as  described  in  Materials  and 
Methods and  stained with Coo- 
massie Blue. The numbers above 
the gel lanes indicate the time of 
digestion in minutes. 
hindered by their crowding together induced by A2.5. 
In view of the possibility that A2.5  can inhibit functions 
mediated by sites on TSP distant from the heparin binding 
domain, one should perhaps interpret with caution the recent 
report  that  polyclonal  antisera  raised  against  the  purified 
heparin binding domain of bovine TSP can inhibit the aggre- 
gation  of bovine platelets (23).  The  authors  of that  report 
suggest that the effect of the antiserum indicates an important 
role for the heparin binding domain in platelet aggregation. 
The possibility must be considered however, that the  poly- 
clonal antiserum can also cause the reorientation of the TSP 
domains observed here with Mab A2.5, and hence could exert 
its effects on platelet aggregation by this indirect mechanism. 
The primary purpose of this study was to map the epitope 
for our Mab C6.7, which has the property of inhibiting the 
aggregation of thrombin- or A23187-stimulated platelets (1). 
The micrographs in Fig. 4 clearly reveal that this Mab binds 
to the outer face of the large globular region, referred to as 
globular region C by Lawler et al. (16).  C6.7 also inhibits the 
hemagglutinating activity of TSP but  has  no effect on  the 
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FIGURE 6  Schematic  representation of the cleavage of the 180-kD 
peptide chain of TSP by chymotrypsin in the  presence  (A) and 
absence (B) of Ca  ++. The NH2 terminal sequence of each fragment 
is indicated by the single letter amino acid code (the sequence of 
the 140/120- and 70-kD peptides using the three letter abbreviation 
system is given in the text). 
agglutination  of fixed platelets (21).  Lawler et al.  (16)  also 
reported a Mab called MA-I which binds to the large globular 
region. No functional effects have been reported for this Mab 
which can be seen in their micrographs of TSP-MA-I com- 
plexes to bind to a different site on the large globular region 
than our MAb C6.7. C6.7 binds to a site directly opposite the 
point at which the connecting strand enters the large domain, 
and MA-I binds to a site about midway between the point of 
connecting strand entry and the epitope for C6.7 (see Fig.  14 
in  reference  16). If in  fact the  epitope recognized by C6.7 
represents the platelet binding site of TSP or the site at which 
it interacts with some other protein that functions in bridge 
formation between  aggregating platelets,  this  site  is ideally 
located to bind in an unhindered fashion to this putative TSP 
receptor. 
Since cross-linking of the large globular regions of TSP by 
C6.7 was only rarely seen at Mab concentrations comparable 
to those used in the platelet aggregation studies (1), we infer 
that the inhibitory action of C6.7  in platelet aggregation is 
due to its direct interference with a platelet binding site in or 
near the  18-kD domain immunoprecipitated by Mab C6.7 
(1). We have previously shown that trimers composed of 140- 
kD chains, and thus devoid of the heparin binding domain, 
can bind to erythrocytes (11)  and  fixed, activated platelets 
(12).  Mab C6.7 precipitates those  140-kD chains, and, after 
cleavage to produce the 120- and 18-kD species and separation 
of the chains, C6.7 precipitates the 18-kD peptide (1). 
The results of the sequencing experiments presented here 
establish  that  both  the  120-kD  fragment and  the  140-kD 
species from which it is derived have identical NH2 termini 
for 11  residues (Fig. 6). This means that the 18-kD fragment 
to which C6.7 binds must be cleaved from the COOH terminal 
end of the  140-kD peptide, as shown in Fig.  6. We (13) and 
others ( 15, 18) have previously shown that the heparin binding 
domain and the intact 18-kD TSP peptide chain have identical 
NH2 terminal sequences,  so the  140-kD fragment must be 
preceded by the heparin binding domain. The heparin domain 
has a  size of 25-35  kD depending on the protease used to 
cleave it (13,  15-18), which suggests that the 25-kD form that 
we isolate from chymotryptic digests is  followed by about 
another 10 kD of peptide in a rather extended conformation. 
In the absence of Ca  ÷÷, both the 140- and 120-kD species are 
1440  THE  JOURNAL  OF  CELL  BIOLOGY  •  VOLUME  101,  1985 
unstable to chymotrypsin, and a  70-kD fragment generated 
from these digests has been shown by Mumby et al. (20) to 
contain a binding site(s) for type V collagen. This peptide also 
has the same sequence at its NH2 terminus as the  140- and 
120-kD peptides generated from Ca  ++ replete TSP. Hence, all 
proteolysis of the subunit except for the initial cleavage that 
liberates  the heparin  binding  domain  proceeds  from  the 
COOH terminus. Therefore, the order of domains within the 
TSP peptide chains would be 
NH2-heparin-type  V collagen-[  ]-fibrinogen-platelet-COOH 
25-35 kD  70 kD  l0 kD  40 kD  18 kD 
The positioning of the fibrinogen binding region is inferred 
from the fact that both the 140- and 120-kD peptides appear 
to bind to fibrinogen (19),  and this region must be distal to 
the 70-kD type V collagen binding domain (20).  It is not yet 
known if the fibrinogen binding region might overlap the type 
V  collagen  binding  region  or the  18-kD  peptide  to  some 
extent. The 10-kD "spacer region" between the type V colla- 
gen domain and the 40-kD fragment that we infer to contain 
the fibrinogen binding site is the COOH terminal peptide, 
which is cleaved from the transient 80-kD species by chymo- 
trypsin in EDTA as shown in Figs. 5 and 6. 
This model for the linear order of the TSP domains implies 
that, at least to some extent, the folded TSP subunit is a co- 
linear representation of the  TSP peptide chain.  This is an 
interesting result since the adhesive glycoprotein fibronectin, 
which is also involved in platelet aggregation (24), has several 
functional domains with binding activities similar to those of 
TSP, and the domains of fibronectin are arranged in a strictly 
co-linear order  along the  peptide  chain,  beginning  with  a 
heparin binding domain at the NH2 terminus (25). In the case 
of TSP,  the  NH2  terminal  heparin  binding  domain  is  a 
compact globular structure that contains no disulfide bonds 
(13). Once the peptide chain exits this domain it does not fold 
back and reenter it but rather proceeds through the connecting 
region where interchain disulfides cross-link the subunits into 
the trimer.  This region, which binds type V  collagen (20), 
remains as the protease-resistant "core" when TSP is digested 
with chymotrypsin in  the absence of Ca  +*. At the ends  of 
these arms, which may be composed of more than one strand 
of peptide chain folded back and forth or arranged in a helical 
conformation,  the  peptide  chain  enters  the  large  globular 
domain. Part of the 70-kD peptide is probably involved in 
forming part of this globular structure,  but apparently can 
adopt a more extended conformation when Ca+* is removed. 
Lawler et al. have reported (16) and we have confirmed that 
upon EDTA treatment of  TSP, the connecting strands become 
longer, and the large globular domains become smaller, as 
though they are unrolling.  Distal to the  70  kD region, the 
peptide chain must fold and become cross-linked with disul- 
fides in a complex pattern, since the 18-kD region containing 
the epitope for C6.7 cannot be obtained from digests without 
both reduction and complete denaturation (1) to allow sepa- 
ration of it from other regions of  the peptide chain with which 
it interacts.  However, this large globular region is probably 
not a single compact domain, since our images of TSP as well 
as those of Lawler et al.  (16) suggest that the large globular 
region is divided into subregions by clefts running across its 
surface. One of these putative subdomains may represent the 
fibrinogen binding region. Further work is needed to localize 
the fibrinogen binding region, which, according to the above model, should be in thelargeglobular domain near theepitope
forC6.7. Since fibrinogen has been suggestedto be the plate-
let-bound receptor for TSP (10, 26, 27), C6.7 may exert its
effects on platelet aggregation by interfering with the TSP-
fibrinogen interaction.
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